Answers are grounded in this paper and cite their sources.
Activation of the G-protein-coupled histamine H1 receptor (H1R) contributes to allergic responses such as bronchoconstriction, vasodilation, and pruritus. This study aimed to computationally prioritize novel fungal-derived compounds for H1R-targeted investigation based on predicted binding characteristics, pharmacokinetic and toxicity profiles, and BBB permeability. A comprehensive workflow incorporating SP and XP molecular docking, ADMET, SAR, DFT, molecular dynamics (MD) simulation, MM/GBSA, and Dynamic Cross-Correlation Matrix (DCCM) analyses was employed. A total of 13,381 fungal-derived natural products from the NPAtlas database were screened using acrivastine as the control. The top ten docking-ranked compounds were further evaluated by ADMET analysis, leading to the prioritization of CID:145,975,830 and CID:145,976,597, which showed docking scores of − 13.654 and − 13.997 kcal/mol, respectively, compared with − 9.071 kcal/mol for the control. Post-docking and post-simulation MM/GBSA analyses provided complementary binding free-energy estimates for the prioritized complexes. PASS prediction associated the leads with anti-eczematic, antipruritic, and vasoprotective activities, while DFT analysis revealed broadly comparable electronic profiles. The 100 ns MD simulations showed differences in dynamic behavior and residue-level interaction persistence, while DCCM analysis indicated differences in correlated residue motions. Overall, CID:145,975,830 exhibited the most consistent computational profile and was prioritized as a candidate for further H1R investigation. Experimental validation is required to establish H1R binding, antagonistic activity, and therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Moshiur et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: